Reuters- Yahoo News Mon Jul 7, 2:47 AM ET
(Reuters) - Teva Pharmaceutical Industries Ltd said data from a late-stage trial showed an increased dose of its multiple sclerosis drug, glatiramer acetate (GA), was not more efficient than an approved lower-dose version of the drug.
Teva was studying the efficacy, safety and tolerability of a 40mg version of GA compared with an approved 20mg version that is sold under the brand name Copaxone.
But the higher dose maintained the favorable safety and tolerability profile of Copaxone, the company, which is evaluating the use of GA for additional indications, said in a statement on Monday.
(Reporting by Pratish Narayanan in Bangalore; Editing by David Holmes)
===========================================
If you want to leave a comment to this article, you need to return-to
(or remain on) - this page
============================================
Mon Jul 7, 2:47 AM ET
(Reuters) - Teva Pharmaceutical Industries Ltd said data from a late-stage trial showed an increased dose of its multiple sclerosis drug, glatiramer acetate (GA), was not more efficient than an approved lower-dose version of the drug.
Teva was studying the efficacy, safety and tolerability of a 40mg version of GA compared with an approved 20mg version that is sold under the brand name Copaxone.
But the higher dose maintained the favorable safety and tolerability profile of Copaxone, the company, which is evaluating the use of GA for additional indications, said in a statement on Monday.
(Reporting by Pratish Narayanan in Bangalore; Editing by David Holmes)
===========================================
If you want to leave a comment to this article, you need to return-to
(or remain on) - this page
============================================